

Key Indices Update

Indices	Close	Change (%)
Nifty	24,609.70	0.82
Sensex	80,951.99	ע0.79
Midcap	56,324.85	0.52 א
Smallcap	17,503.10	ע0.26

Trend Strength Indicator


Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
32	1275/ <mark>1582</mark>

Key Data

Data	Current	Previous
Dow Jones	41,910.5	41,904.5
U.S. Dollar Index	99.76	99.54
Brent Crude (USD/BBL)	64.18	64.53
US 10Y Bond Yield (%)	4.53	4.59
India 10Y Bond Yield (%)	6.26	6.26

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	54962.30	لا 0.20
NIFTYAUTO	23497.55	0.85
NIFTYENERG	35400.65	0.69
NIFTYFINSR	28161.25	u.46 ك
NIFTYFMCG	55606.80	ו.43
NIFTYIT	37134.10	וב 1.08
NIFTYMEDIA	1673.45	1.077
NIFTYMETAL	9194.00	ע0.15
NIFTYPHARM	21529.10	ل ا0.90
NIFTYREALT	935.95	ע0.29



Market Radiance

ick : Read : Repeat

Top News

- + Premier Explosives announced a dividend of ₹0.50 per share (25%) for FY25, subject to shareholder approval at the upcoming AGM. The dividend will be paid within 30 days of approval.
- + Tata Steel has inaugurated the Phase II expansion of its Kalinganagar plant in Odisha, boosting its crude steel capacity from 3 to 8 million tonnes per annum (MTPA). This expansion, representing a ₹27,000 crore investment, aims to produce advanced high-strength steels for various sectors.

Technical

Refer Page 03-04


- + Nifty edged lower after a brief respite, losing nearly a percent, weighed down by weak global cues.
- + Following a gap-down start, the **Nifty continued to drift lower for most of the weekly expiry session.**
- However, it rebounded in the final hours after retesting the crucial support zone of the short-term moving average – the 20-day EMA – around the 24,450 level, and eventually closed at 24,609.70.
- + In line with the benchmark's movement, **all key sectoral indices ended in the red**, with FMCG, IT, and auto among the top losers.
- + Going forward, it is crucial for the Nifty to hold above its 20-day EMA support near 24,450.
- + A breach of this level may trigger further profit-taking, potentially dragging the index down to the 24,100 mark.
- + Stock of the day FORTIS



Market Radiance

Fundamental

Top News





Market Radiance Click : Read : Repeat

Technical

Tested support at 20DEMA. Maintain caution.

NIFTY	S1	S2	RI	R2
24609.70 🎽 203.75 (0.82%)	24450	24200	24850	25000

Technical Chart : Daily



- Nifty edged lower after a brief respite, losing nearly a percent, weighed down by weak global cues.
- However, it rebounded in the final hours after retesting the crucial support zone of the short-term moving average – the 20-day EMA – around the 24,450 level, and eventually closed at 24,609.70.
- + Going forward, it is crucial for the Nifty to hold above its 20-day EMA support near 24,450.
- + A breach of this level may trigger further profit-taking, potentially dragging the index down to the 24,100 mark.

BANKNIFTY	S1	\$2	RI	R2	
54941.30 뇌 133.80 (0.24%)	54500	54100	55400	55800	



- The banking index recovered from its intraday low after initial losses and closed marginally negative.
- + Mixed trend continued among the banking majors wherein Indusindbk witnessed gains while PNB and Axisbank remained top losers.
- The index reversed taking support of its 20 EMA which shows resilience at lower levels but must hold the 54600-54400 zone to avoid further decline.
- On the upside, the index need decisive close above 55500-55700 for continuation of the uptrend.
- + Traders should keep a close watch on these levels and align their positions accordingly.



Market Radiance

Technical

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
FORTIS	BUY	723.80	720-725	695	775

Technical Chart : Weekly



 Name
 Price
 Price %

 TTML
 74.50
 7.837

 FORTIS
 723.00
 7.587

 JUBLPHARMA
 1045.00
 5.157

 PNBHOUSING
 1042.70
 0.77¥

419.50

لا 1.64

- + Fortis exhibits a strong rising structure, trading near record highs.
- + The stock has rebounded sharply after retesting its long term moving average i.e.200 DEMA.
- + It is set for a fresh upward rally following the completion of its corrective phase.
- + Traders can retain an optimistic stance and look for buying opportunity in the stock.

Name	Price	Price %	-
SOLARINDS	15060.00	6.127	Rang
ASTRAL	1447.00	5.037	ge Bre reakd
ZYDUSLIFE	904.00	1.617	idow
LUPIN	1968.00	ו-1.40	eakout/ Iown
COLPAL	2486.00	6.52	

Name	Price	Price %	T
ABFRL	90.80	لا 7.35	Fop 5
COLPAL	2486.50	6.50 كا	F&O
PEL	1092.50	4.08	
BSE	7015.00	¥3.97	Losers
DIXON	15170.00	لا 2.83	Ľ

Name	Price	Price %	_
CHAMBLFERT	591.70	لا2.01	Bearish
COLPAL	2486.50	6.50 ۷	
DIXON	15170.00	لا 2.83	Charts
M&M	3016.00	2.42 צ	rts
ONGC	242.10	2.65	

Momentum Stocks Midcap

OIL

Bullish Charts

Name	Price	Price %
SOLARINDS	15060.00	6.127
ASTRAL	1446.00	4.967
NMDC	71.90	2.497
MFSL	1425.80	2.087
POLICYBZR	1762.00	2.047

Name	Price	Price %
ANGELONE	2909.00	1.497
ASTRAL	1446.00	4.967
DALBHARAT	2116.90	1.327
NATIONALUM	184.91	1.747
SOLARINDS	15060.00	6.127



Market Radiance Click : Read : Repeat

Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Rajan Gupta	rajan.gupta1@religare.com



Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/ are as under:

Statements on ownership and material conflicts of interest, compensation- Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	atement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Market Radiance

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results



